Table 95Subgroup and sensitivity analyses: haloperidol vs. aripiprazole – Response rates

Response RatesStudiesParticipantsEffect EstimateI2Favors
OVERALL POOLED RESULTS621751.01 (0.76, 1.34)83%ND
Disorder subtypes
Schizoaffective included35310.93 (0.41, 2.11)87%ND
Mixed or schizoaffective disorder excluded216540.94 (0.75, 1.16)74%ND
Co-morbid drug/alcohol use
Excluded37670.89 (0.57, 1.38)64%ND
Mixed214181.13 (0.62, 2.06)94%ND
First time vs. other
Mixed first and previous episodes48911.06 (0.72, 1.57)79%ND
Multiple episodes only112940.85 (0.75, 0.96)NEaripiprazole
Treatment resistance
Treatment resistant excluded317781.10 (0.80, 1.51)89%ND
Mixed21080.35 (0.03, 3.93)69%ND
Duration of followup
>6weeks213930.37 (0.04, 3.76)68%ND
≤6weeks37921.12 (0.80, 1.57)80%ND
Dosage of FGA (haloperidol)
<15mg/d420610.90 (0.73, 1.11)60%ND
Up to 30mg/d11241.55 (1.20, 2.00)NEhaloperidol
Dosage of SGA (aripiprazole)
Up to 30mg/d420610.90 (0.73, 1.11)60%ND
>30mg/d11241.55 (1.20, 2.00)NEhaloperidol
Source of funding
Industry funding420610.90 (0.73, 1.11)60%ND
No industry funding reported11241.55 (1.20, 2.00)NEhaloperidol
Risk of bias
Unclear316540.94 (0.75, 1.16)74%ND
High25310.93 (0.41, 2.11)87%ND

Significant results are in bold. d = day; FGA = first generation antipsychotic; I2 = I–squared; ND = no difference; NE = not estimable; mg = milligrams; SGA = second generation antipsychotic

From: Appendix M, Subgroup and Sensitivity Analyses

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 63.
Abou-Setta AM, Mousavi SS, Spooner C, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.